ADIL FY2024 EPS Forecast Lifted by Litchfield Hills Research

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Analysts at Litchfield Hills Research increased their FY2024 earnings estimates for Adial Pharmaceuticals in a report issued on Thursday, November 21st. Litchfield Hills Research analyst T. O’neill now expects that the company will post earnings of ($1.31) per share for the year, up from their previous forecast of ($1.82). The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q4 2024 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.33) EPS.

Several other equities research analysts have also recently commented on ADIL. Rodman & Renshaw began coverage on Adial Pharmaceuticals in a research note on Thursday, November 14th. They set a “buy” rating and a $8.00 target price for the company. RODMAN&RENSHAW raised shares of Adial Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, November 14th.

Adial Pharmaceuticals Price Performance

ADIL stock opened at $1.01 on Monday. The stock has a 50-day moving average price of $1.02 and a 200-day moving average price of $1.10. Adial Pharmaceuticals has a 1-year low of $0.77 and a 1-year high of $4.17.

Institutional Trading of Adial Pharmaceuticals

A hedge fund recently bought a new stake in Adial Pharmaceuticals stock. Virtu Financial LLC acquired a new position in shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,469 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned about 0.48% of Adial Pharmaceuticals at the end of the most recent quarter. Institutional investors own 16.41% of the company’s stock.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.